Ramucirumab

Ramucirumab?
Monoclonal antibody
Type Whole antibody
Source Human
Target VEGFR2 (KDR)
Clinical data
Trade names Cyramza
  • Approved
Identifiers
947687-13-0 
None
UNII D99YVK4L0X Yes
Chemical data
Formula C6374H9864N1692O1996S46
143.6 kDa
  (what is this?)  (verify)

Ramucirumab[1] (IMC-1121B, trade name Cyramza[2][3]) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis.[4] This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax. J code?

Approved uses

On April 21, 2014, the FDA approved ramucirumab, as a single agent or with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma if the disease has progressed despite fluoropyrimidine- or platinum-containing chemotherapy.[5][6]

On December 12, 2014, the FDA approved ramucirumab in combination with docetaxel, for treatment of metastatic non-small-cell lung carcinoma with disease progression on or after platinum-containing chemotherapy. If the cancer has a sensitizing mutation of EGFR or ALK previous therapy should have included targeted therapy for the genomic tumor aberration.[7]

Other

On September 26, 2013 the manufacturer Eli Lilly announced that its Phase III study for ramucirumab failed to hit its primary endpoint on progression-free survival among women with metastatic breast cancer.[8][9]

In June 2014, the drug failed a second phase III trial when the compound failed to show statistical significance in the overall survival of patients with liver cancer.[10]


References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ramucirumab, American Medical Association.
  2. ↑ FierceBiotech: FDA OKs Lilly's blockbuster hopeful ramucirumab for stomach cancer
  3. ↑ Cyramza official website
  4. ↑ Ramucirumab (Cyramza) package insert
  5. ↑ FDA.gov press release for ramucirumab approval, accessed April 22, 2014
  6. ↑ Ramucirumab gastric cancer regimen & reference
  7. ↑
  8. ↑ Clinical trial number NCT00703326 for "Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer" at ClinicalTrials.gov
  9. ↑ Fierce Biotech. "In another stinging setback, Eli Lilly's ramucirumab fails PhIII breast cancer study". Retrieved 27 September 2013.
  10. ↑ http://www.genengnews.com/gen-news-highlights/lilly-s-cyramza-fails-phase-iii-trial-in-liver-cancer/81249964/